Concentrations of tilmicosin in mammary gland secretions of dairy cows following subcutaneous administration of one or two doses of an experimental preparation of tilmicosin and its efficacy against intramammary infections caused by Staphylococcus aureus

Jesus Mendoza Department of Physiology and Pharmacology, National Autonomous University of Mexico (UNAM), Mexico City, Mexico 04510.

Search for other papers by Jesus Mendoza in
Current site
Google Scholar
PubMed
Close
 DVM, MSC
,
Ismael Martínez-Cortés Department of Medicine of Ruminants, National Autonomous University of Mexico (UNAM), Mexico City, Mexico 04510.

Search for other papers by Ismael Martínez-Cortés in
Current site
Google Scholar
PubMed
Close
 DVM, MSc
,
Reyes López-Ordaz Department of Agricultural and Animal Production, Autonomous Metropolitan University, Mexico City, Mexico 04960.

Search for other papers by Reyes López-Ordaz in
Current site
Google Scholar
PubMed
Close
 DVM, MSC
,
Lilia Gutiérrez Department of Physiology and Pharmacology, National Autonomous University of Mexico (UNAM), Mexico City, Mexico 04510.

Search for other papers by Lilia Gutiérrez in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
, and
Hector Sumano Department of Physiology and Pharmacology, National Autonomous University of Mexico (UNAM), Mexico City, Mexico 04510.

Search for other papers by Hector Sumano in
Current site
Google Scholar
PubMed
Close
 DVM, PhD

Abstract

OBJECTIVE To determine the concentration of tilmicosin in mammary gland secretions of dairy cows following administration of an experimental preparation once or twice during the dry period (45-day period immediately prior to calving during which cows are not milked) and to evaluate its efficacy for the treatment of cows with intramammary infections (IMIs) caused by Staphylococcus aureus at dry off (cessation of milking; first day of dry period), compared with that of an intramammary infusion of ceftiofur.

ANIMALS 172 cows.

PROCEDURES Milk samples were collected for microbiological culture 5 days before dry off and at calving and 15 and 30 days after calving. Cows with Staphylococcus IMIs were randomly assigned to receive an experimental preparation of tilmicosin (20 mg/kg, SC) once at dry off (n = 58) or at dry off and again 20 days later (56) or receive a long-acting intramammary preparation of ceftiofur (500 mg/mammary gland; 56) at dry off. Mammary gland secretions were collected from 5 cows in the tilmicosin-treated groups every 5 days after dry off until calving for determination of tilmicosin concentration.

RESULTS Mean maximum concentration of tilmicosin in mammary gland secretions ranged from 14.4 to 20.9 μg/mL after the first dose and was 17.1 μg/mL after the second dose. The bacteriologic cure rate was 100% for all 3 treatments. Tilmicosin was detectable for 0 and 18 days after calving in the milk of cows treated with 1 and 2 doses of tilmicosin, respectively.

CONCLUSIONS AND CLINICAL RELEVANCE Administration of an experimental preparation of tilmicosin (20 mg/kg, SC) once to dairy cows at dry off might be useful for the treatment of S aureus IMIs.

Abstract

OBJECTIVE To determine the concentration of tilmicosin in mammary gland secretions of dairy cows following administration of an experimental preparation once or twice during the dry period (45-day period immediately prior to calving during which cows are not milked) and to evaluate its efficacy for the treatment of cows with intramammary infections (IMIs) caused by Staphylococcus aureus at dry off (cessation of milking; first day of dry period), compared with that of an intramammary infusion of ceftiofur.

ANIMALS 172 cows.

PROCEDURES Milk samples were collected for microbiological culture 5 days before dry off and at calving and 15 and 30 days after calving. Cows with Staphylococcus IMIs were randomly assigned to receive an experimental preparation of tilmicosin (20 mg/kg, SC) once at dry off (n = 58) or at dry off and again 20 days later (56) or receive a long-acting intramammary preparation of ceftiofur (500 mg/mammary gland; 56) at dry off. Mammary gland secretions were collected from 5 cows in the tilmicosin-treated groups every 5 days after dry off until calving for determination of tilmicosin concentration.

RESULTS Mean maximum concentration of tilmicosin in mammary gland secretions ranged from 14.4 to 20.9 μg/mL after the first dose and was 17.1 μg/mL after the second dose. The bacteriologic cure rate was 100% for all 3 treatments. Tilmicosin was detectable for 0 and 18 days after calving in the milk of cows treated with 1 and 2 doses of tilmicosin, respectively.

CONCLUSIONS AND CLINICAL RELEVANCE Administration of an experimental preparation of tilmicosin (20 mg/kg, SC) once to dairy cows at dry off might be useful for the treatment of S aureus IMIs.

Contributor Notes

Address correspondence to Dr. Sumano (sumano@unam.mx).
  • 1. Halasa T, Østerås O, Hogeveen H, et al. Meta-analysis of dry cow management for dairy cattle. Part 1. Protection against new intramammary infections. J Dairy Sci 2009; 92: 31343149.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2. Pezeshki A, Capuco AV, De Spiegeleer B, et al. An integrated view on how the management of the dry period length of lactating cows could affect mammary biology and defence. J Anim Physiol Anim Nutr (Berl) 2010; 94: e7e30.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3. Cameron M, Keefe GP, Roy JP, et al. Evaluation of selective dry cow treatment following on-farm culture: milk yield and somatic cell count in the subsequent lactation. J Dairy Sci 2015; 98: 24272436.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4. Capuco AV, Akers RM, Smith JJ. Mammary growth in Holstein cows during the dry period: quantification of nucleic acids and histology. J Dairy Sci 1997; 80: 477487.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5. Green MJ, Bradley AJ, Medley GF, et al. Cow, farm, and management factors during the dry period that determine the rate of clinical mastitis after calving. J Dairy Sci 2007; 90: 37643776.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6. Scherpenzeel CG, den Uijl IE, van Schaik G, et al. Evaluation of the use of dry cow antibiotics in low somatic cell count cows. J Dairy Sci 2014; 97: 36063614.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7. Green MJ, Green LE, Medley GF, et al. Influence of dry period bacterial intramammary infection on clinical mastitis in dairy cows. J Dairy Sci 2002; 85: 25892599.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8. Halasa T, Huijps K, Østerås O, et al. Economic effects of bovine mastitis and mastitis management: a review. Vet Q 2007; 29: 1831.

  • 9. Gundelach Y, Kalscheuer E, Hamann H, et al. Risk factors associated with bacteriological cure, new infection, and incidence of clinical mastitis after dry cow therapy with three different antibiotics. J Vet Sci 2011; 12: 227233.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10. Nickerson SC, Owens WE, Fox LK, et al. Comparison of tilmicosin and cephapirin as therapeutics for Staphylococcus aureus mastitis at dry-off. J Dairy Sci 1999; 82: 696703.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11. Dingwell RT, Duffield TF, Leslie KE, et al. The efficacy of intramammary tilmicosin at drying-off, and other risk factors for the prevention of new intramammary infections during the dry period. J Dairy Sci 2002; 85: 32503259.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12. Barkema HW, Schukken YH, Zadoks RN. Invited review: the role of cow, pathogen, and treatment regimen in the therapeutic success of bovine Staphylococcus aureus mastitis. J Dairy Sci 2006; 89: 18771895.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13. Brouillette E, Grondin G, Shkreta L, et al. In vivo and in vitro demonstration that Staphylococcus aureus is an intracellular pathogen in the presence or absence of fibronectin-binding proteins. Microb Pathog 2003; 35: 159168.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 14. Dingwell RT, Leslie KE, Duffield TF, et al. Efficacy of intramammary tilmicosin and risk factors for cure of Staphylococcus aureus infection in the dry period. J Dairy Sci 2003; 86: 159168.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 15. Experimental preparation of tilmicosin. Patent submission No. 212148. México City: Instituto Mexicano de la Protección Industrial, 2013.

    • Search Google Scholar
    • Export Citation
  • 16. Ziv G, Shem-Tov M, Glickman A, et al. Tilmicosin antibacterial activity and pharmacokinetics in cows. J Vet Pharmacol Ther 1995; 18: 340345.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 17. Buret AG. Immuno-modulation and anti-inflammatory benefits of antibiotics: the example of tilmicosin. Can J Vet Res 2010; 74: 110.

    • Search Google Scholar
    • Export Citation
  • 18. Scorneaux B, Shryock RT. Intracellular accumulation, subcellular distribution, and efflux of tilmicosin in bovine mammary, blood, and lung cells. J Dairy Sci 1999; 82: 12021212.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 19. Mexican Official Standard NOM-062-ZOO-1999. Technical specifications for the production, care and use of laboratory animals. United Mexican States Department of Agriculture, Livestock, Rural Development, Fisheries and Food. Available at: www.fmvz.unam.mx/fmvz/principal/archivos/062ZOO.PDF. Accessed May 26, 2015.

    • Search Google Scholar
    • Export Citation
  • 20. NMC. Procedures for collecting milk samples. Available at: www.nmconline.org/sampling.htm. Accessed Jan 12, 2014.

  • 21. NMC. Using bulk tank milk cultures in a dairy practice. Available at: www.nmconline.org/articles/bulktank.htm. Accessed Jan 12, 2014.

    • Search Google Scholar
    • Export Citation
  • 22. Carter GR. Diagnostic procedures in veterinary bacteriology and mycology. 4th ed. Springfield, Ill: Charles C Thomas Publisher Ltd, 1984; 570577.

    • Search Google Scholar
    • Export Citation
  • 23. Parker RM, Patel RK. Determination of tilmicosin in ovine milk using high-performance liquid chromatography. Analyst 1994; 119: 25772579.

  • 24. SAS user's guide: statistics (version 9.1.3). Cary, NC: SAS Institute Inc Press, 2012;421–479.

  • 25. Littell CR, Milliken AG, Stroup WW, et al. SAS system for mixed models. Cary, NC: SAS Institute Inc Press, 1996;160165.

  • 26. Bonnier M, Doré C, Amédéo J, et al. In vitro activity of tylosin and tilmicosin against cocci isolated from bovine mastitis. Revue Méd Vét 2006; 157: 486489.

    • Search Google Scholar
    • Export Citation
  • 27. Gehring R, Smith GW. An overview of factors affecting the disposition of intramammary preparations used to treat bovine mastitis. J Vet Pharmacol Ther 2006; 29: 237241.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 28. Sandgren CH, Waller KP, Emanuelson U. Therapeutic effects of systemic or intramammary antimicrobial treatment of bovine subclinical mastitis during lactation. Vet J 2008; 175: 108117.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 29. Gruet P, Maincent P, Berthelot X, et al. Bovine mastitis and intramammary drug delivery: review and perspectives. Adv Drug Deliv Rev 2001; 50: 245259.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 30. Kalmus P, Simojoki H, Orro T, et al. Efficacy of 5-day parenteral versus intramammary benzylpenicillin for treatment of clinical mastitis caused by gram-positive bacteria susceptible to penicillin in vitro. J Dairy Sci 2014; 97: 21552164.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 31. Helton-Groce SL, Thomson TD, Readnour RS. A study of tilmicosin in milk following subcutaneous administration to lactating dairy cows. Can Vet J 1993; 34: 619621.

    • Search Google Scholar
    • Export Citation
  • 32. McDougall S, Agnew EK, Cursons R, et al. Parenteral treatment of clinical mastitis with tylosin base or penethamate hydriodide in dairy cattle. J Dairy Sci 2007; 90: 779789.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 33. Avci T, Elmas M. Milk and blood pharmacokinetics of tylosin and tilmicosin following parenteral administrations to cows. Scientific World Journal 2014; 2014: 869096.

    • Search Google Scholar
    • Export Citation
  • 34. Owens WE, Nickerson SC, Ray CH. Efficacy of parenterally or intramammarily administered tilmicosin or ceftiofur against Staphylococcus aureus mastitis during lactation. J Dairy Sci 1999; 82: 645647.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 35. Wang W, Song Y, Petrovski K, et al. Development of intramammary delivery systems containing lasalocid for the treatment of bovine mastitis: impact of solubility improvement on safety, efficacy, and milk distribution in dairy cattle. Drug Des Devel Ther 2015; 9: 631642.

    • Search Google Scholar
    • Export Citation
  • 36. Adams HR. Veterinary pharmacology and therapeutics. 8th ed. Ames, Iowa: Iowa State University Press, 2001; 876882.

  • 37. Sensitivity chart for delvotest SP-NT & delvotest BLF, for antibiotic products commonly used on UK dairy farms. Millwood Products, Bath, England. Available at: www.millwoodproducts.co.uk/public/backend/uploads/imagemanager/documents/Detailed%20SSensitivit%20Chart%20for%20Delvotest%20SP-NT%20&%20BLF.pdf. Accessed Apr 4, 2016.

    • Search Google Scholar
    • Export Citation

Advertisement